drugset / Trial / NCT00880490

Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00880490

Phase 1/2 Completed 34 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2008-11
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject PT005 Unknown 2.4 ug Inhaled
Subject PT005 Unknown 4.8 ug Inhaled
Subject PT005 Unknown 9.6 ug Inhaled
Subject PT005 Unknown 12 ug Inhaled